BACKGROUND: Patients with the Shwachman-Diamond syndrome often develop hematologic complications. No risk factors for these complications have so far been identified. The aim of this study was to classify the hematologic complications occurring in patients with Shwachman-Diamond syndrome and to investigate the risk factors for these complications. DESIGN AND METHODS: One hundred and two patients with Shwachman-Diamond syndrome, with a median follow-up of 11.6 years, were studied. Major hematologic complications were considered in the case of definitive severe cytopenia (i.e. anemia <7 g/dL or thrombocytopenia <20 × 10(9)/L), classified as malignant (myelodysplasia/leukemia) according to the 2008 World Health Organization classification or as non-malignant. RESULTS: Severe cytopenia was observed in 21 patients and classified as malignant severe cytopenia (n=9), non-malignant severe cytopenia (n=9) and malignant severe cytopenia preceded by non-malignant severe cytopenia (n=3). The 20-year cumulative risk of severe cytopenia was 24.3% (95% confidence interval: 15.3%-38.5%). Young age at first symptoms (<3 months) and low hematologic parameters both at diagnosis of the disease and during the follow-up were associated with severe hematologic complications (P<0.001). Fifteen novel SBDS mutations were identified. Genotype analysis showed no discernible prognostic value. CONCLUSIONS Patients with Shwachman-Diamond syndrome with very early symptoms or cytopenia at diagnosis (even mild anemia or thrombocytopenia) should be considered at a high risk of severe hematologic complications, malignant or non-malignant. Transient severe cytopenia or an indolent cytogenetic clone had no deleterious value.
BACKGROUND:Patients with the Shwachman-Diamond syndrome often develop hematologic complications. No risk factors for these complications have so far been identified. The aim of this study was to classify the hematologic complications occurring in patients with Shwachman-Diamond syndrome and to investigate the risk factors for these complications. DESIGN AND METHODS: One hundred and two patients with Shwachman-Diamond syndrome, with a median follow-up of 11.6 years, were studied. Major hematologic complications were considered in the case of definitive severe cytopenia (i.e. anemia <7 g/dL or thrombocytopenia <20 × 10(9)/L), classified as malignant (myelodysplasia/leukemia) according to the 2008 World Health Organization classification or as non-malignant. RESULTS: Severe cytopenia was observed in 21 patients and classified as malignant severe cytopenia (n=9), non-malignant severe cytopenia (n=9) and malignant severe cytopenia preceded by non-malignant severe cytopenia (n=3). The 20-year cumulative risk of severe cytopenia was 24.3% (95% confidence interval: 15.3%-38.5%). Young age at first symptoms (<3 months) and low hematologic parameters both at diagnosis of the disease and during the follow-up were associated with severe hematologic complications (P<0.001). Fifteen novel SBDS mutations were identified. Genotype analysis showed no discernible prognostic value. CONCLUSIONS Patients with Shwachman-Diamond syndrome with very early symptoms or cytopenia at diagnosis (even mild anemia or thrombocytopenia) should be considered at a high risk of severe hematologic complications, malignant or non-malignant. Transient severe cytopenia or an indolent cytogenetic clone had no deleterious value.
Authors: Yigal Dror; Jean Donadieu; Jutta Koglmeier; John Dodge; Sanna Toiviainen-Salo; Outi Makitie; Elizabeth Kerr; Cornelia Zeidler; Akiko Shimamura; Neil Shah; Marco Cipolli; Taco Kuijpers; Peter Durie; Johanna Rommens; Liesbeth Siderius; Johnson M Liu Journal: Ann N Y Acad Sci Date: 2011-12 Impact factor: 5.691
Authors: J Fleitz; S Rumelhart; F Goldman; D Ambruso; R J Sokol; D Pacini; R Quinones; M Holida; N Lee; R Tannous; R Giller Journal: Bone Marrow Transplant Date: 2002-01 Impact factor: 5.483
Authors: S Cesaro; G Guariso; E Calore; M V Gazzola; R Destro; S Varotto; L Zanesco; C Messina Journal: Bone Marrow Transplant Date: 2001-01 Impact factor: 5.483
Authors: E Maserati; A Minelli; C Olivieri; L Bonvini; A Marchi; M Bozzola; C Danesino; S Scappaticci; F Pasquali Journal: Cancer Genet Cytogenet Date: 2000-09
Authors: Yigal Dror; Peter Durie; Hedy Ginzberg; Rebecca Herman; Anu Banerjee; Martin Champagne; Kevin Shannon; David Malkin; Melvin H Freedman Journal: Exp Hematol Date: 2002-07 Impact factor: 3.084
Authors: Kasiani C Myers; Elissa Furutani; Edie Weller; Bradford Siegele; Ashley Galvin; Valerie Arsenault; Blanche P Alter; Farid Boulad; Carlos Bueso-Ramos; Lauri Burroughs; Paul Castillo; James Connelly; Stella M Davies; Courtney D DiNardo; Iftikhar Hanif; Richard H Ho; Nicole Karras; Michelle Manalang; Lisa J McReynolds; Taizo A Nakano; Grzegorz Nalepa; Maxim Norkin; Matthew J Oberley; Etan Orgel; Yves D Pastore; Joseph Rosenthal; Kelly Walkovich; Jordan Larson; Maggie Malsch; M Tarek Elghetany; Mark D Fleming; Akiko Shimamura Journal: Lancet Haematol Date: 2019-12-23 Impact factor: 18.959
Authors: Noemi A Zambetti; Eric M J Bindels; Paulina M H Van Strien; Marijke G Valkhof; Maria N Adisty; Remco M Hoogenboezem; Mathijs A Sanders; Johanna M Rommens; Ivo P Touw; Marc H G P Raaijmakers Journal: Haematologica Date: 2015-07-16 Impact factor: 9.941
Authors: Daria V Babushok; Hongbo M Xie; Jacquelyn J Roth; Nieves Perdigones; Timothy S Olson; Joshua D Cockroft; Xiaowu Gai; Juan C Perin; Yimei Li; Michele E Paessler; Hakon Hakonarson; Gregory M Podsakoff; Philip J Mason; Jaclyn A Biegel; Monica Bessler Journal: Br J Haematol Date: 2013-10-14 Impact factor: 6.998
Authors: Kasiani Myers; Kyle Hebert; Joseph Antin; Farid Boulad; Lauri Burroughs; Inga Hofmann; Rammurti Kamble; Margaret L MacMillan; Mary Eapen Journal: Biol Blood Marrow Transplant Date: 2020-05-16 Impact factor: 5.742